- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients
- Dermata continues discussions with potential botulinum toxin partners for DMT410
- Raised $2.3 million in net proceeds from financing completed in 2Q 2024
Read More